-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Reiterates Buy on Pasithea Therapeutics, Maintains $3 Price Target

Benzinga·04/20/2026 16:27:39
Listen to the news
HC Wainwright & Co. analyst Sara Nik reiterates Pasithea Therapeutics (NASDAQ:KTTA) with a Buy and maintains $3 price target.